Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
Kamada Ltd., a global biopharmaceutical company (NASDAQ: KMDA), announced FDA approval of its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory for measuring rabies-neutralizing antibodies. This state-of-the-art lab in Israel expands Kamada's testing capabilities for its key anti-rabies products KEDRAB® and KAMRAB®, supporting…